Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial.

ABSTRACT:

Purpose

A clinical study to characterize renal masses with positron emission tomography/computed tomography (PET/CT) was undertaken.

Patients and methods

This was an open-label multicenter study of iodine-124 ((124)I) -girentuximab PET/CT in patients with renal masses who were scheduled for resection. PET/CT and contrast-enhanced CT (CECT) of the abdomen were performed 2 to 6 days after intravenous (124)I-girentuximab administration and before resection of the renal mass(es). Images were interpreted centrally by three blinded readers for each imaging modality. Tumor histology was determined by a blinded central pathologist. The primary end points-average sensitivity and specificity for clear cell renal cell carcinoma (ccRCC)-were compared between the two modalities. Agreemen

SUBMITTER: Divgi CR 

PROVIDER: S-EPMC5795663 | biostudies-literature | 2013 Jan

REPOSITORIES: biostudies-literature